# Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

> **NCT01206101** · PHASE2 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 3 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01206101
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03-21
- **Primary completion:** 2013-06-03
- **Final completion:** 2013-06-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well as challenges relating to trial execution and study completion.
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206101, "Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01206101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*